Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 8/20 | 0.49 |
| ▸ | FSHR | P23945 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026901 | 0.90 | BRAF (0.49) | BRAF | |
| SCHEMBL6222764 | 0.88 | LHCGR (0.52) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL5030864 | 0.87 | LHCGR (0.68) | LHCGRFSHRTSHRBRAF | |
| SCHEMBL5026184 | 0.86 | LHCGR (0.48) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL6222882 | 0.84 | LHCGR (0.48) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL6223952 | 0.84 | LHCGR (0.48) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL5026188 | 0.83 | LHCGR (0.51) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL6224284 | 0.80 | LHCGR (0.50) | LHCGRFSHRTSHRBRAFKMT2A | |
| SCHEMBL5026190 | 0.78 | BRAF (0.51) | LHCGRFSHRBRAF | |
| SCHEMBL5030944 | 0.77 | BRAF (0.47) | LHCGRFSHRTSHRBRAFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | LHCGR 3/4885FSHR 1/4885TSHR 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.